References
- Meier F, Will S, Ellwanger U et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br. J. Dermatol. 147(1), 62–70 (2002).
- Pollock PM, Meltzer PS. A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2(1), 5–7 (2002).
- Sosman JA, Kim KB, Schuchter L et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366(8), 707–714 (2012).
- Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, Phase 3 randomised controlled trial. Lancet 380(9839), 358–365 (2012).
- Nazarian R, Shi H, Wang Q et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468(7326), 973–977 (2010).
- Adjei AA, Cohen RB, Franklin W et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase ½ inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 26(13), 2139–2146 (2008).
- Flaherty KT, Robert C, Hersey P et al.; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367(2), 107–114 (2012).
- Bagrodia S, Smeal T, Abraham RT. Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies. Pigment Cell Melanoma Res. 25(6), 819–831 (2012).
- Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367(18), 1694–1703 (2012).
- Davies MA, Liu P, McIntyre S et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117(8), 1687–1696 (2011).
- Chapman PB, Hauschild A, Robert C et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507–2516 (2011).
- Straussman R, Morikawa T, Shee K et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487(7408), 500–504 (2012).
- Yancovitz M, Litterman A, Yoon J et al. Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS ONE 7(1), e29336 (2012).
- Croteau W, Jenkins MH, Ye S, Mullins DW, Brinckerhoff CE. Differential mechanisms of tumor progression in clones from a single heterogeneous human melanoma. J. Cell. Physiol. 228(4), 773–780 (2013).
- Little AS, Smith PD, Cook SJ. Mechanisms of acquired resistance to ERK1/2 pathway inhibitors. Oncogene 32(10), 1207–1215 (2012).
- Bollag G, Tsai J, Zhang J et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat. Rev. Drug Discov. 11(11), 873–886 (2012).
- Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464(7287), 427–430 (2010).
- Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010).
- Slominski A, Zmijewski MA, Pawelek J. l-tyrosine and l-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions. Pigment Cell Melanoma Res. 25(1), 14–27 (2012).
- Slominski A, Zbytek B, Slominski R. Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells. Int. J. Cancer 124(6), 1470–1477 (2009).